Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 126
Filter
Add more filters

Publication year range
1.
Respir Res ; 25(1): 323, 2024 Aug 24.
Article in English | MEDLINE | ID: mdl-39182102

ABSTRACT

BACKGROUND: Complicated pleural infection comprises of complex effusions and empyema. When tube thoracostomy is ineffective, treatment options include surgical drainage, deloculation and decortication or intrapleural fibrinolysis. We performed a systematic review and meta-analysis to examine which technique is superior in treating complicated pleural infections. METHODS: PubMed, MEDLINE and EMBASE databases were searched for studies published between January 2000 to July 2023 comparing surgery and intrapleural fibrinolysis for treatment of complicated pleural infection. The primary outcome was treatment success. Secondary outcomes included hospital length of stay, chest drain duration and in-hospital mortality. RESULTS: Surgical management of complicated pleural infections was more likely to be successful than intrapleural fibrinolysis (RR 1.18; 95% CI 1.02, 1.38). Surgical intervention group benefited from statistically significant shorter hospital length of stay (MD: 3.85; 95% CI 1.09, 6.62) and chest drain duration (MD: 3.42; 95% CI 1.36, 5.48). There was no observed difference between in-hospital mortality (RR: 1.00; 95% CI 0.99, 1.02). CONCLUSION: Surgical management of complicated pleural infections results in increased likelihood of treatment success, shorter chest drain duration and hospital length of stay in the adult population compared with intrapleural fibrinolysis. In-hospital mortality did not differ. Large cohort and randomized research need to be conducted to confirm these findings.


Subject(s)
Thrombolytic Therapy , Humans , Thrombolytic Therapy/methods , Empyema, Pleural/surgery , Empyema, Pleural/mortality , Empyema, Pleural/diagnosis , Treatment Outcome , Hospital Mortality , Drainage/methods , Length of Stay , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/therapeutic use , Fibrinolysis/drug effects , Pleural Effusion/surgery , Pleural Effusion/therapy
2.
Surg Endosc ; 34(4): 1641-1647, 2020 04.
Article in English | MEDLINE | ID: mdl-31286249

ABSTRACT

OBJECTIVE: Thoracic empyema in uremic patients on maintenance hemodialysis is a challenging situation. The clinical characteristics are rarely reported, and the surgical outcomes remain unclear. We report our experience with video-assisted thoracoscopic surgery in these patients during 10-year period of time. METHODS: Between 2005 and 2015, we retrospectively reviewed the clinical characteristics, bacteriological studies, and thoracoscopic surgical results of 23 empyema patients undergoing maintenance hemodialysis. RESULTS: The mean patient age was 67.1 ± 12.9 years. All patients had additional preexisting systemic diseases. The mean duration of hemodialysis was 34.7 ± 25.8 months. The infections causing empyema were pneumonia in 11 (47.8%), blood stream infection in 8 (34.8%), and uremic pleuritis in 4 (17.4%). Among the 22 identified microorganisms, the most common pathogen was methicillin-resistant Staphylococcus aureus (31.8%). After thoracoscopic surgery, 8 patients (34.8%) required additional procedures for complications, including 2 patients who required repeated thoracoscopy for hemothorax and 6 (26.1%) patients who required open drainage for residual empyema. The mean hospital stay was 62.4 days, and 6 patients (26.1%) died in the hospital. Univariate and multivariate analyses revealed that maintenance hemodialysis longer than 5 years was a significant factor associated with in-hospital mortality (odds ratio: 14.8, 95% confidence interval 1.5-151.6; p < 0.0001). CONCLUSION: While surgical management of thoracic empyema in uremic patients undergoing maintenance hemodialysis is associated with high rates of complication and mortality, thoracoscopic surgery is feasible, especially for patients undergoing hemodialysis for less than 5 years.


Subject(s)
Empyema, Pleural/surgery , Renal Dialysis , Thoracic Surgery, Video-Assisted/mortality , Thoracic Surgery, Video-Assisted/methods , Aged , Aged, 80 and over , Drainage/adverse effects , Empyema, Pleural/etiology , Empyema, Pleural/mortality , Female , Hospital Mortality , Humans , Length of Stay , Male , Methicillin-Resistant Staphylococcus aureus/pathogenicity , Middle Aged , Pneumonia/complications , Postoperative Care , Postoperative Complications/etiology , Renal Dialysis/adverse effects , Retrospective Studies , Staphylococcal Infections/complications , Staphylococcal Infections/microbiology , Thoracic Surgery, Video-Assisted/adverse effects
3.
J Trop Pediatr ; 65(3): 231-239, 2019 Jun 01.
Article in English | MEDLINE | ID: mdl-30053189

ABSTRACT

OBJECTIVES: The purposes of this paper are to study clinicobacteriological profile, treatment modalities and outcome of pediatric empyema thoracis and to identify changes over a decade. DESIGN: This is a retrospective study. SETTING: Department of Pediatrics of a tertiary care hospital in North India. PATIENTS: We enrolled 205 patients (1 month-12 years) of empyema thoracis admitted over 5 years (2007-11) and compared the profile with that of a previous study from our institute (1989-98). RESULTS: Pleural fluid cultures were positive in 40% (n = 82) cases from whom 87 isolates were obtained. Staphylococcus aureus was the most common isolate (66.7%). Methicillin-sensitive S. aureus accounted for 56%, Methicillin-resistant S. aureus (MRSA) 10% and gram-negative organisms 18.3% of isolates. Intercostal drainage tube (ICDT) was inserted in 97.5%, intrapleural streptokinase was administered in 33.6%, and decortication performed in 27.8% cases. Duration of hospital stay was 17.2 (±6.3) days, duration of antibiotic (intravenous and oral) administration was 23.8 (±7.2) days and mortality rate was 4%. In the index study (compared with a previous study), higher proportion of cases received parenteral antibiotics (51.7% vs. 23.4%) and ICDT insertion (20.5% vs. 7%) before referral and had disseminated disease (20.5% vs. 14%) and septic shock (11.2% vs. 1.6%), less culture positivity (40% vs. 48%), more MRSA (10.3% vs. 2.5%) and gram-negative organisms (18.4% vs. 11.6%), increased use of intrapleural streptokinase and surgical interventions (27.8% vs. 19.7%), shorter hospital stay (17 vs. 25 days) and higher mortality (3.9% vs. 1.6%). CONCLUSIONS: Over a decade, an increase in the incidence of empyema caused by MRSA has been noticed, with increased use of intrapleural streptokinase and higher number of surgical interventions.


Subject(s)
Drainage/methods , Empyema, Pleural/therapy , Fibrinolytic Agents/administration & dosage , Streptokinase/administration & dosage , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/complications , Child , Child, Preschool , Drug Administration Schedule , Empyema, Pleural/diagnosis , Empyema, Pleural/drug therapy , Empyema, Pleural/mortality , Female , Fibrinolytic Agents/therapeutic use , Gram-Negative Bacteria/isolation & purification , Humans , Incidence , Length of Stay/statistics & numerical data , Male , Methicillin-Resistant Staphylococcus aureus , Staphylococcal Infections/complications , Staphylococcus aureus/isolation & purification , Streptokinase/therapeutic use , Treatment Outcome
4.
Lung ; 196(5): 623-629, 2018 10.
Article in English | MEDLINE | ID: mdl-30099584

ABSTRACT

PURPOSE: Complicated parapneumonic effusions and empyema are a leading cause of morbidity in the United States with over 1 million admissions annually and a mortality rate that remains high in spite of recent advances in diagnosis and treatment. The identification of high risk patients is crucial for improved management and the provision of cost-effective care. The RAPID score is a scoring system comprised of the following variables: renal function, age, purulence, infection source, and dietary factors and has been shown to predict outcomes in patients with pleural space infections. METHODS: In a single center retrospective study, we evaluated 98 patients with complicated parapneumonic effusions and empyema who had tube thoracostomy (with or without Intrapleural fibrinolytic therapy) and assessed treatment success rates, mortality, length of hospital stay, and direct hospitalization costs stratified by three RAPID score categories: low-risk (0-2), medium risk (3-4), and high-risk (5-7) groups. RESULTS: Treatment success rate was 71%, and the 90 day mortality rate was 12%. There was a positive-graded association between the low, medium and high RAPID score categories and mortality, (5.3%, 8.3% and 22.6%, respectively), length of hospital stay (10, 21, 19 days, respectively), and direct hospitalization costs ($19,909, $36,317 and $43,384, respectively). CONCLUSION: Our findings suggest that the RAPID score is a robust tool which could be used to identify patients with complicated parapneumonic effusions and empyema who may be at an increased risk of mortality, prolonged hospitalization, and who may incur a higher cost of treatment. Randomized controlled trials identifying the most effective initial treatment modality for medium- and high-risk patients are needed.


Subject(s)
Empyema, Pleural/therapy , Hospital Costs , Length of Stay/statistics & numerical data , Pleural Effusion/therapy , Thoracentesis , Thoracostomy , Adult , Aged , Chest Tubes , Empyema, Pleural/economics , Empyema, Pleural/mortality , Female , Humans , Kaplan-Meier Estimate , Length of Stay/economics , Male , Middle Aged , Mortality , Paracentesis , Pleural Effusion/economics , Pleural Effusion/mortality , Retrospective Studies , Risk Assessment , Thoracic Surgery, Video-Assisted , Thrombolytic Therapy , Treatment Outcome
5.
BMC Pulm Med ; 18(1): 160, 2018 Oct 12.
Article in English | MEDLINE | ID: mdl-30314475

ABSTRACT

BACKGROUND: We explored the hypothesized importance of early knowledge of microbiological etiology in patients with pleural infection, including comorbidity and treatment factors in the outcome analyses. METHODS: Data from the medical records of a large cohort of 437 consecutive patients in 9 hospitals in East-Denmark were included retrospectively. RESULTS: Microbiology, co-morbidity, therapy and outcome are described in detail. Patient groups with microbiology negative and known bacterial etiology had a similar 30-day and 90-day mortality. There were no differences in initial antibiotic treatment regimens, antibiotic treatment duration, rate of intra-pleural fibrinolysis treatment, surgical referral rate, and ICU admittance rate. Patients with microbiology negative etiology were younger (60.8 vs 64.3 years) and fewer had predisposing risk factors (59% vs 71%), but pleural drainage was more often delayed (49% vs 36%). Mortality was similar in patients treated with either of the two nationally recommended initial antibiotic regimens. However, higher 90-day mortality (22.5% vs 9.7%), disease severity (31.5% vs 6.2%), and ICU admittance rate (21.3% vs 2.9%) was observed in a sub-group with initial broad-spectrum treatment compared to patients receiving the nationally recommended initial treatments, irrespective of knowledge of etiology. Several factors correlated independently to 90-day mortality, including age, predisposing risk factors, surgical referral (Odds-Ratios > 1), drainage delay and intra-pleural fibrinolysis (ORs < 1). CONCLUSIONS: No difference was found between patients with microbiology negative and known bacterial etiology regarding outcome or treatment parameters. Treatment factors and predisposing factors independently relating to mortality were found in the cohort. Broad-spectrum antibiotics were initially used for treatment of patients with more severe illness and poorer outcome.


Subject(s)
Bacterial Infections/mortality , Bacterial Infections/therapy , Empyema, Pleural/mortality , Empyema, Pleural/therapy , Aged , Anti-Bacterial Agents/therapeutic use , Comorbidity , Denmark/epidemiology , Drainage/methods , Empyema, Pleural/microbiology , Female , Humans , Intensive Care Units/statistics & numerical data , Logistic Models , Male , Middle Aged , Multivariate Analysis , Retrospective Studies , Risk Factors , Severity of Illness Index , Time Factors
6.
Anaerobe ; 49: 95-98, 2018 Feb.
Article in English | MEDLINE | ID: mdl-29325875

ABSTRACT

We report the case of a 69-year-old man admitted for septic shock secondary to necrotic pneumoniae complicated by thoracic empyema of fatal issue. Microbiological examination of pleural liquid revealed a mixed anaerobic flora involving Campylobacter rectus and Actinomyces meyeri. Campylobacter rectus is an infrequent anaerobic pathogen of oral origin To our knowledge, this is the first case report of fatal C. rectus - associated thoracic empyema, and only the second reported case in which identification was successfully performed by MALDI-TOF MS.


Subject(s)
Campylobacter Infections/microbiology , Campylobacter rectus/physiology , Empyema, Pleural/microbiology , Aged , Anti-Bacterial Agents/administration & dosage , Campylobacter Infections/drug therapy , Campylobacter Infections/mortality , Campylobacter rectus/drug effects , Campylobacter rectus/genetics , Campylobacter rectus/isolation & purification , Empyema, Pleural/drug therapy , Empyema, Pleural/mortality , Fatal Outcome , Humans , Male
7.
Cochrane Database Syst Rev ; 3: CD010651, 2017 Mar 17.
Article in English | MEDLINE | ID: mdl-28304084

ABSTRACT

BACKGROUND: Empyema refers to pus in the pleural space, commonly due to adjacent pneumonia, chest wall injury, or a complication of thoracic surgery. A range of therapeutic options are available for its management, ranging from percutaneous aspiration and intercostal drainage to video-assisted thoracoscopic surgery (VATS) or thoracotomy drainage. Intrapleural fibrinolytics may also be administered following intercostal drain insertion to facilitate pleural drainage. There is currently a lack of consensus regarding optimal treatment. OBJECTIVES: To assess the effectiveness and safety of surgical versus non-surgical treatments for complicated parapneumonic effusion or pleural empyema. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2016, Issue 9), MEDLINE (Ebscohost) (1946 to July week 3 2013, July 2015 to October 2016) and MEDLINE (Ovid) (1 May 2013 to July week 1 2015), Embase (2010 to October 2016), CINAHL (1981 to October 2016) and LILACS (1982 to October 2016) on 20 October 2016. We searched ClinicalTrials.gov and WHO International Clinical Trials Registry Platform for ongoing studies (December 2016). SELECTION CRITERIA: Randomised controlled trials that compared a surgical with a non-surgical method of management for all age groups with pleural empyema. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trials for inclusion and risk of bias, extracted data, and checked the data for accuracy. We contacted trial authors for additional information. We assessed the quality of the evidence using the GRADE approach. MAIN RESULTS: We included eight randomised controlled trials with a total of 391 participants. Six trials focused on children and two on adults. Trials compared tube thoracostomy drainage (non-surgical), with or without intrapleural fibrinolytics, to either VATS or thoracotomy (surgical) for the management of pleural empyema. Assessment of risk of bias for the included studies was generally unclear for selection and blinding but low for attrition and reporting bias. Data analyses compared thoracotomy versus tube thoracostomy and VATS versus tube thoracostomy. We pooled data for meta-analysis where appropriate. We performed a subgroup analysis for children along with a sensitivity analysis for studies that used fibrinolysis in non-surgical treatment arms.The comparison of open thoracotomy versus thoracostomy drainage included only one study in children, which reported no deaths in either treatment arm. However, the trial showed a statistically significant reduction in mean hospital stay of 5.90 days for those treated with primary thoracotomy. It also showed a statistically significant reduction in procedural complications for those treated with thoracotomy compared to thoracostomy drainage. We downgraded the quality of the evidence for length of hospital stay and procedural complications outcomes to moderate due to the small sample size.The comparison of VATS versus thoracostomy drainage included seven studies, which we pooled in a meta-analysis. There was no statistically significant difference in mortality or procedural complications between groups. This was true for both adults and children with or without fibrinolysis. However, mortality data were limited: one study reported one death in each treatment arm, and seven studies reported no deaths. There was a statistically significant reduction in mean length of hospital stay for those treated with VATS. The subgroup analysis showed the same result in adults, but there was insufficient evidence to estimate an effect for children. We could not perform a separate analysis for fibrinolysis for this outcome because all included studies used fibrinolysis in the non-surgical arms. We downgraded the quality of the evidence to low for mortality (due to wide confidence intervals and indirectness), and moderate for other outcomes in this comparison due to either high heterogeneity or wide confidence intervals. AUTHORS' CONCLUSIONS: Our findings suggest there is no statistically significant difference in mortality between primary surgical and non-surgical management of pleural empyema for all age groups. Video-assisted thoracoscopic surgery may reduce length of hospital stay compared to thoracostomy drainage alone.There was insufficient evidence to assess the impact of fibrinolytic therapy.A number of common outcomes were reported in the included studies that were not directly examined in our primary and secondary outcomes. These included duration of chest tube drainage, duration of fever, analgesia requirement, and total cost of treatment. Future studies focusing on patient-centred outcomes, such as patient functional scores, and other clinically relevant outcomes, such as radiographic improvement, treatment failure rates, and amount of fluid drainage, are needed to inform clinical decisions.


Subject(s)
Empyema, Pleural/therapy , Thoracic Surgery, Video-Assisted , Thoracostomy , Adult , Child , Drainage/adverse effects , Drainage/methods , Drainage/mortality , Empyema, Pleural/mortality , Empyema, Pleural/surgery , Humans , Length of Stay , Randomized Controlled Trials as Topic , Selection Bias , Thoracic Surgery, Video-Assisted/adverse effects , Thoracic Surgery, Video-Assisted/mortality , Thoracostomy/adverse effects , Thoracostomy/mortality , Thrombolytic Therapy
8.
Zentralbl Chir ; 141(3): 335-40, 2016 Jun.
Article in German | MEDLINE | ID: mdl-26863158

ABSTRACT

BACKGROUND: The surgical treatment of pleural empyema should be carried out depending on the stage of the disease and the patient's symptoms. The aim of this study was to evaluate the outcomes of surgical pleural empyema treatment. PATIENTS AND METHODS: Retrospective analysis of all patients with pleural empyema treated surgically between January 2008 and December 2013. The primary endpoint of the study was inpatient lethality. Secondary endpoints included duration of inpatient stay, type of treatment (surgical/conservative), proof of pathogen and type, alteration and duration of antibiotic therapy. RESULTS: Of 359 patients, 0.8 % (n = 3) had stage I empyema, 50.4 % (n = 181) had stage II and 48.7 % (n = 175) had stage III. The most frequent causes (32.4 %) included acute pneumonia (parapneumonic pleural empyema), surgery (usually thoracic) in 18.0 % of cases and previous pneumonia (postpneumonic pleural empyema) in 15.4 %. Surgery was performed in 86 % of cases (operative procedures: open thoracotomy 85 %, VATS 15 %). The average duration of inpatient stay was 20 days for stages II and III. Recovery following VATS was significantly shorter in stage II compared to thoracotomy (p = 0.022). Hospital lethality amounted to 7.0 % (25 patients). The lethality rate was 5.5 % (10/185) in stage II and 8.6 % (15/175) in stage III. Patients with confirmed pathogens had a significantly worse mortality rate across all stages (9.8 %) than patients with no confirmed pathogens (4.0 %, p = 0.034). Age, malignant underlying disease, multiple comorbidities, immunosuppression, a change in antibiotic regimens and sepsis were significant risk factors. CONCLUSION: The inpatient lethality of patients with pleural empyema correlates with the stage of the condition. Positive confirmation of pathogens, sepsis, a higher age, multiple comorbidities, malignant tumour disease, immunosuppression and a change of antibiotics are negative prognostic factors.


Subject(s)
Bacterial Infections/classification , Bacterial Infections/surgery , Empyema, Pleural/classification , Empyema, Pleural/surgery , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/mortality , Combined Modality Therapy , Empyema, Pleural/mortality , Female , Germany , Hospital Mortality , Humans , Length of Stay , Male , Middle Aged , Pneumonectomy/methods , Retrospective Studies , Risk Factors , Thoracentesis/methods , Thoracic Surgery, Video-Assisted/methods , Thoracotomy/methods
9.
Klin Khir ; (10): 9-11, 2016 Oct.
Article in English, Ukrainian | MEDLINE | ID: mdl-30479104

ABSTRACT

Immediate and late results of the combined gastrectomy (CG) performance in 719 patients, suffering locally­spread gastric cancer (LSGC), were analyzed. Additional resection of adjacent оrgans was performed in 165 observations. In early postoperative period complications in 116 (16.1%) patients have had occurred, including surgical complications ­ in 77.7%, and nonsurgical ­ in 22.3%. Lethality in 30 postoperative days have constituted 11.1%. Тhe patients' postoperative life time was at average (22.9 ± 1.67) mo, mediana­ 9.3 mo; indices of 3­year and 5­year survival ­ (18.9 ± 1.72) and (12.9 ± 1.51)%,accordingly. Essential difference in favor of subtotal distal gastric resection was established, basing on comparison data between this procedure and CG. The data obtained witnessed the expediency of combined operative interventions, what have had widened possibilities of the patients' radical treatment for LSGC.


Subject(s)
Esophageal Neoplasms/surgery , Gastrectomy/methods , Intestinal Neoplasms/surgery , Liver Neoplasms/surgery , Pancreatic Neoplasms/surgery , Splenic Neoplasms/surgery , Stomach Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Empyema, Pleural/diagnosis , Empyema, Pleural/etiology , Empyema, Pleural/mortality , Empyema, Pleural/pathology , Esophageal Neoplasms/mortality , Esophageal Neoplasms/secondary , Female , Gastrectomy/adverse effects , Humans , Intestinal Neoplasms/mortality , Intestinal Neoplasms/secondary , Intestinal Obstruction/diagnosis , Intestinal Obstruction/etiology , Intestinal Obstruction/mortality , Intestinal Obstruction/pathology , Liver Neoplasms/mortality , Liver Neoplasms/secondary , Male , Middle Aged , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/secondary , Peritonitis/diagnosis , Peritonitis/etiology , Peritonitis/mortality , Peritonitis/pathology , Postoperative Complications/diagnosis , Postoperative Complications/etiology , Postoperative Complications/mortality , Postoperative Complications/pathology , Retrospective Studies , Splenic Neoplasms/mortality , Splenic Neoplasms/secondary , Stomach/pathology , Stomach/surgery , Stomach Neoplasms/mortality , Stomach Neoplasms/pathology , Survival Analysis , Time Factors , Treatment Outcome
10.
Zentralbl Chir ; 140 Suppl 1: S22-8, 2015 Oct.
Article in German | MEDLINE | ID: mdl-26351760

ABSTRACT

INTRODUCTION: Parapneumonic pleural effusions arise from pneumonia and may develop into pleural empyema (PE). PE is defined as collection of pus in the pleural space with secondary inflammation of the visceral and parietal pleura. This review article describes the current treatment strategies for para- and postpneumonic PE both in children and adults. MATERIAL AND METHODS: Selective literature research via Medline (key words: pleural empyema, pleural empyema in children, thoracic empyema) and presentation of our own clinical experience with therapy recommendations. RESULTS: The incidence of postpneumonic PE is increasing in both children and adults. PE is associated with a high morbidity and mortality if it is not treated early and adequate. Progression of PE follows a characteristic morphological course, which is classified in three stages: the exsudative, fibrinopurulent, and organizing phase. Treatment should be adapted to these three phases including systemic antibiotic therapy and drainage of the pleural space. Intrapleural fibrinolysis can be performed with good success independent of age in the transition of stage 1 and 2. In persistent PE (stage 2), thoracoscopic decortication is recommended to avoid progression into the organizing phase (stage 3) with the need of an open decortication. In debilitated elderly patients the increasing use of intrathoracic vacuum therapy (Mini-VAC/Mini-VAC-instill) offers an effective and less invasive therapy option. CONCLUSION: Para- and postpneumonic PE requires an individualized and stage adapted therapy using a combination of medical and surgical treatment strategies with the aims of removing the source of infection and ensuring re-establishment of lung expansion.


Subject(s)
Empyema, Pleural/surgery , Pneumonia, Bacterial/surgery , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Child , Combined Modality Therapy , Cross-Sectional Studies , Empyema, Pleural/classification , Empyema, Pleural/diagnosis , Empyema, Pleural/mortality , Humans , Pleura/surgery , Pneumonia, Bacterial/classification , Pneumonia, Bacterial/complications , Pneumonia, Bacterial/diagnosis , Pneumonia, Bacterial/mortality , Survival Rate , Thoracentesis , Thoracoscopy , Thrombolytic Therapy
11.
J Formos Med Assoc ; 113(4): 210-8, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24512757

ABSTRACT

BACKGROUND/PURPOSE: Acute thoracic empyema is a common clinical problem worldwide, resulting in substantial morbidity and mortality. The objective of this study was to report its clinical characteristics and to evaluate whether thoracoscopic surgery is associated with a lower rate of in-hospital mortality compared with nonoperative drainage. METHODS: Between 2001 and 2010, we retrospectively reviewed the clinical characteristics, bacteriological studies, and treatment outcomes of 602 patients with acute thoracic empyema. Thoracoscopic surgery was performed in 417 (69.2%) patients, while the remaining patients underwent nonoperative drainage. After treatment, 77 patients (12.8%) died in the hospital. A propensity score-based process, matched on potential risk factors for in-hospital mortality, was performed to select patients with equalized potential prognostic factors in the thoracoscopy and nonoperative groups. The log-rank test was used to compare the survival time with discharge between the two matched groups. RESULTS: Multivariate analysis showed that age, malignancy, chronic lung disease, chronic renal insufficiency, liver cirrhosis, polymicrobial infection, and positive bacterial culture were risk factors for in-hospital mortality. The propensity score-matched analysis showed that the in-hospital mortality difference was significant (p = 0.014) and the Kaplan-Meier survival analysis revealed a higher survival rate to discharge (p < 0.001 by log-rank test), both favoring thoracoscopy over nonoperative drainage. CONCLUSION: Acute thoracic empyema carries a high mortality rate, especially in elderly patients with coexisting medical conditions and polymicrobial and positive bacterial cultures. Our study results also showed that thoracoscopy is feasible and might provide better chances for survival in borderline operable patients than nonoperative drainage.


Subject(s)
Empyema, Pleural/surgery , Thoracic Surgery, Video-Assisted , Acute Disease , Adult , Aged , Empyema, Pleural/mortality , Female , Hospital Mortality , Humans , Male , Middle Aged , Propensity Score , Retrospective Studies
12.
Clinics (Sao Paulo) ; 79: 100356, 2024.
Article in English | MEDLINE | ID: mdl-38608555

ABSTRACT

OBJECTIVE: This study aims to correlate the RAPID score with the 3-month survival and surgical results of patients undergoing lung decortication with stage III pleural empyema. METHODS: This was a retrospective study with the population of patients with pleural empyema who underwent pulmonary decortication between January 2019 and June 2022. Data were collected from the institution's database, and patients were classified as low, medium, and high risk according to the RAPID score. The primary outcome was 3-month mortality. Secondary outcomes were the length of hospital stay, readmission rate, and the need for pleural re-intervention. RESULTS: Of the 34 patients with pleural empyema, according to the RAPID score, patients were stratified into low risk (23.5 %), medium risk (47.1 %), and high risk (29.4 %). The high-risk group had a 3-month mortality of 40 %, while the moderate-risk group had a 6.25 % and the low-risk group had no deaths within 90 days, confirming a good correlation with the RAPID score (p < 0.05). Sensitivity and specificity for the primary outcome in the high-risk score were 80.0 % and 79.3 %, respectively. The secondary outcomes did not reach statistical significance. CONCLUSIONS: In this retrospective series, the RAPID score had a good correlation with 3-month mortality in patients undergoing lung decortication. The morbidity indicators did not reach statistical significance. The present data justifies further studies to explore the capacity of the RAPID score to be used as a selection tool for treatment modality in patients with stage III pleural empyema.


Subject(s)
Empyema, Pleural , Length of Stay , Postoperative Complications , Humans , Empyema, Pleural/mortality , Empyema, Pleural/surgery , Male , Retrospective Studies , Female , Middle Aged , Aged , Postoperative Complications/mortality , Length of Stay/statistics & numerical data , Adult , Risk Assessment/methods , Risk Factors , Treatment Outcome
13.
Eur J Cardiothorac Surg ; 66(1)2024 Jul 01.
Article in English | MEDLINE | ID: mdl-38979769

ABSTRACT

OBJECTIVES: Although intrapleural administration of fibrinolytics is an important treatment option for the management of empyema, the addition of fibrinolytics failed to reduce the need for surgery and mortality in previous randomized controlled trials. This study aimed to investigate the effects of administrating fibrinolytics in the early phase (within 3 days of chest tube insertion) of empyema compared with late administration or no administration. METHODS: We used the Japanese Diagnosis Procedure Combination Inpatient Database to identify patients aged ≥16 years who were hospitalized and underwent chest tube drainage for empyema. A 1:2 propensity score matching and stabilized inverse probability of treatment weighting were conducted. RESULTS: Among the 16 265 eligible patients, 3082 and 13 183 patients were categorized into the early and control group, respectively. The proportion of patients who underwent surgery was significantly lower in the early fibrinolytics group than in the control group; the odds ratio (95% confidence interval) was 0.69 (0.54-0.88) in the propensity score matching (P = 0.003) and 0.64 (0.50-0.80) in the stabilized inverse probability of treatment weighting analysis (P < 0.001). All-cause 30-day in-hospital mortality, length of hospital stay, duration of chest tube drainage, and total hospitalization costs were also more favourable in the early fibrinolytics group. CONCLUSIONS: The early administration of fibrinolytics may reduce the need for surgery and death in adult patients with empyema.


Subject(s)
Chest Tubes , Drainage , Empyema, Pleural , Fibrinolytic Agents , Humans , Male , Female , Drainage/methods , Fibrinolytic Agents/administration & dosage , Fibrinolytic Agents/therapeutic use , Empyema, Pleural/surgery , Empyema, Pleural/mortality , Empyema, Pleural/drug therapy , Middle Aged , Aged , Propensity Score , Retrospective Studies , Adult , Japan/epidemiology , Length of Stay/statistics & numerical data , Hospital Mortality
14.
Thorac Cancer ; 15(15): 1201-1207, 2024 May.
Article in English | MEDLINE | ID: mdl-38597111

ABSTRACT

BACKGROUND: This study investigated the role of the thoracic skeletal muscle mass as a marker of sarcopenia on postoperative mortality in pleural empyema. METHODS: All consecutive patients (n = 103) undergoing surgery for pleural empyema in a single tertiary referral center between January 2020 and December 2022 were eligible for this study. Thoracic skeletal muscle mass index (TSMI) was determined from preoperative computed tomography scans. The impact of TSMI and other potential risk factors on postoperative in-hospital mortality was retrospectively analyzed. RESULTS: A total of 97 patients were included in this study. The in-hospital mortality rate was 13.4%. In univariable analysis, low values for preoperative TSMI (p = 0.020), low preoperative levels of thrombocytes (p = 0.027) and total serum protein (p = 0.046) and higher preoperative American Society of Anesthesiologists (ASA) category (p = 0.007) were statistically significant risk factors for mortality. In multivariable analysis, only TSMI (p = 0.038, OR 0.933, 95% CI: 0.875-0.996) and low thrombocytes (p = 0.031, OR 0.944, 95% CI: 0.988-0.999) remained independent prognostic factors for mortality. CONCLUSIONS: TSMI was a significant prognostic risk factor for postoperative mortality in patients with pleural empyema. TSMI may be suitable for risk stratification in this disease with high morbidity and mortality, which may have further implications for the selection of the best treatment strategy.


Subject(s)
Empyema, Pleural , Muscle, Skeletal , Humans , Male , Female , Empyema, Pleural/surgery , Empyema, Pleural/mortality , Middle Aged , Case-Control Studies , Muscle, Skeletal/pathology , Muscle, Skeletal/surgery , Retrospective Studies , Aged , Prognosis , Risk Factors , Hospital Mortality
15.
Respiration ; 86(4): 288-94, 2013.
Article in English | MEDLINE | ID: mdl-23988906

ABSTRACT

BACKGROUND: The role of drainage, intrapleural fibrinolytics, and/or surgery in the management of thoracic empyema is controversial. OBJECTIVES: We aimed to investigate the operational practice of empyema management at our hospital. METHODS: Between January 2001 and December 2008, all patients with thoracic empyema were retrieved. After exclusion of patients with malignant effusion, traumatic or iatrogenic empyema, and a history of pleurodesis or tuberculosis, we compared the characteristics of medically versus surgically treated empyema patients. RESULTS: Seventy-eight of 215 retrieved patients were acute bacterial empyema cases. All received intravenous antibiotics. Fifty-eight (74.4%) initially received tube thoracostomy, 34 (43.6%) were treated with intrapleural urokinase, and 30 (38.5%) were operated on. Of 20 patients without initial tube thoracostomy, 15 (75%) were operated on, compared to 9 (37.5%) who were initially treated by tube thoracostomy without intrapleural fibrinolytics (OR 5; 95% CI 1.4-18.5, p = 0.01) and 6 (17.7%) who were initially treated with tube thoracostomy and intrapleural urokinase (OR 14; 95% CI 3.6-53.6, p < 0.001). The surgery patients were not different in demographic and clinical characteristics but were more likely to describe significant chest pain 12 months after discharge. CONCLUSIONS: In this retrospective cohort study of thoracic empyema patients, initial chest tube insertion and intrapleural fibrinolytics were associated with less surgical therapy. Other predictors of the need for surgery could not be identified. Surgery patients were more likely to suffer from residual chest pain 12 months after discharge. Initial treatment with IV antibiotics, chest tube, and intrapleural fibrinolytics was successful in the majority of patients.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Empyema, Pleural/drug therapy , Empyema, Pleural/surgery , Aged , Chest Pain/etiology , Empyema, Pleural/mortality , Female , Humans , Male , Middle Aged , Retrospective Studies , Switzerland/epidemiology , Thoracotomy/adverse effects
16.
Thorac Cardiovasc Surg ; 61(7): 612-8, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23754321

ABSTRACT

BACKGROUND: The association of pleural empyema and lung cancer has traditionally been considered as a contraindication for lung resection. However, several aspects of this problem still remain controversial. MATERIALS AND METHODS: A retrospective study was conducted including 15 patients (12 pneumonectomies and 3 lobectomies) who underwent a lung resection for primary lung cancer after previous pleural empyema. RESULTS: In all but one patient, empyema was treated by chest tube for 15 to 40 days. In only two patients, the diagnosis of empyema preceded the diagnosis of lung cancer. Among patients with pneumonectomy, a good intrapleural cleavage plane existed in only one patient with no signs of infection. In each patient with a lobectomy, preoperative chest tube aspiration took 20 to 30 days and in none of them intraoperative signs of infection existed. In patients with pneumonectomy, empyema without bronchopleural fistula occurred in two patients, while in one patient, empyema was associated with fistula. The operative morbidity after pneumonectomy was 33.3%. CONCLUSION: Association of pleural empyema and lung cancer is not an absolute contraindication for surgery. Potentially curative operation is possible, provided a full control of infection is achieved.


Subject(s)
Drainage , Empyema, Pleural/therapy , Lung Neoplasms/surgery , Pneumonectomy , Adult , Aged , Chest Tubes , Contraindications , Drainage/adverse effects , Drainage/instrumentation , Drainage/mortality , Empyema, Pleural/complications , Empyema, Pleural/diagnosis , Empyema, Pleural/mortality , Female , Humans , Lung Neoplasms/complications , Lung Neoplasms/diagnosis , Lung Neoplasms/mortality , Male , Middle Aged , Patient Selection , Pneumonectomy/mortality , Retrospective Studies , Risk Factors , Serbia , Survival Analysis , Tomography, X-Ray Computed , Treatment Outcome
17.
Ann Plast Surg ; 70(6): 680-3, 2013 Jun.
Article in English | MEDLINE | ID: mdl-22868324

ABSTRACT

BACKGROUND: Infection of thoracic aortic grafts occurs infrequently; however, once present, it is associated with high patient morbidity and mortality. We report our successful experience in the treatment of 11 patients who developed infection of their thoracic aortic graft. METHODS: This is an institutional review board-approved retrospective review of 11 patients who had documented thoracic aortic graft infections with associated mediastinitis or empyema. After diagnosis, plastic surgery consultation was obtained, and the patients underwent formal operative debridement with cardiovascular service. Intraoperative cultures were obtained, and the patients were placed on specific antibiotic regimens. After the wound bed was adequately prepared, the omentum was harvested and was based on the right gastroepiploic vessels. The flap was circumferentially wrapped around the aortic graft and simultaneously used to fill the mediastinal dead space. In a certain subset of patients, a cryopreserved homograft replaced the synthetic graft before omental flap reconstruction. RESULTS: The infections were eventually controlled in all surviving patients. Ten of 11 patients were discharged either to a rehab or to a nursing facility. There was 1 perioperative death secondary to multisystem organ failure. Mean follow-up period was 36 months and revealed a greater than 90% survival rate. Serial imaging reported no suture-line complications. CONCLUSIONS: We report our series on the treatment of patients with infection of thoracic aortic grafts. Debridement and tissue coverage with an omental flap provided these patients with successful recovery and survival.


Subject(s)
Aorta, Thoracic/surgery , Blood Vessel Prosthesis/adverse effects , Omentum/surgery , Prosthesis-Related Infections/surgery , Staphylococcal Infections/surgery , Surgical Flaps , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Combined Modality Therapy , Empyema, Pleural/drug therapy , Empyema, Pleural/etiology , Empyema, Pleural/mortality , Empyema, Pleural/surgery , Female , Follow-Up Studies , Humans , Male , Mediastinitis/drug therapy , Mediastinitis/etiology , Mediastinitis/mortality , Mediastinitis/surgery , Middle Aged , Prosthesis-Related Infections/complications , Prosthesis-Related Infections/drug therapy , Prosthesis-Related Infections/mortality , Retrospective Studies , Staphylococcal Infections/complications , Staphylococcal Infections/drug therapy , Staphylococcal Infections/mortality , Survival Rate , Treatment Outcome
18.
Chirurgia (Bucur) ; 108(5): 695-9, 2013.
Article in English | MEDLINE | ID: mdl-24157115

ABSTRACT

OBJECTIVE: The aim of this study is to analyse the possibilities and the results of using the serratus anterior muscle flap during reoperations in patients with a complicated course after major general thoracic procedures. MATERIAL AND METHODS: We performed a retrospective study on 25 consecutive patients operated in a single center between 01.01.2002-01.01.2012, in whom we used the serratus anterior muscle flap during complex thoracomyoplasty procedures for postoperative empyema. In all cases the serratus anterior was mobilized keeping both the thoraco-dorsal branch and the lateral thoracic vessels intact. The following parameters were followed: mortality rate, morbidity rate, hospitalization,viability of the flap and the functional status of the patients at 3 months after surgery. RESULTS: We encountered one postoperative death (4%) and one recurrence of the intrathoracic suppuration (4%). Intensive care unit hospitalization ranged between 1-9 days, with a median of 2 days. Overall postoperative hospitalization ranged between 8-87, with a median of 34 days. We have encountered no post-operative flap necrosis. At 3 months after surgery, 92% of the survivors returned to a normal life. The type of the first thoracotomy incision (postero-lateral versus antero-lateral) had no statistically significant impact on the outcome of the patients' hospitalization or rate of local complications(p 0.05). CONCLUSIONS: As a pure muscular flap, the serratus anterior is extremely useful to treat infectious complications after general thoracic surgery procedures. It can be used during thoracomyoplasty procedures with an acceptable mortality and morbidity and with good functional results.


Subject(s)
Back Muscles/transplantation , Empyema, Pleural/surgery , Surgical Flaps , Thoracoplasty , Adolescent , Adult , Aged , Empyema, Pleural/complications , Empyema, Pleural/mortality , Female , Follow-Up Studies , Humans , Length of Stay , Male , Middle Aged , Retrospective Studies , Thoracoplasty/methods , Treatment Outcome
19.
Scand J Infect Dis ; 43(6-7): 430-5, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21366407

ABSTRACT

BACKGROUND: Pleural empyema is a serious condition with a considerable mortality rate and morbidity. This study evaluated the correlations between several potential prognostic factors (age, predisposing diseases, early drainage, insufficient initial antimicrobial therapy, thoracic surgical treatment, intrapleural fibrinolysis, and nosocomial status) and outcome. METHODS: Danish patients with positive pleural cultures attending 3 hospitals over a 9-y period, were identified in the laboratory databases. Clinical details and outcome were evaluated retrospectively by audit of the medical records. RESULTS: We included 158 patients in this study. The overall mortality was 27% and the median length of stay was 29 days. Mortality correlated independently with several factors: nosocomial infection (odds ratio (OR) 2.62, 95% confidence interval (CI) 1.71-4.16), predisposing conditions (OR 2.17, 95% CI 1.50-3.14), and also with the possibly interventional factors of sufficient initial antimicrobial therapy (OR 0.45, 95% CI 0.31-0.65), thoracic surgery treatment (OR 0.27, 95% CI 0.14-0.52) and local fibrinolytic therapy (OR 0.13, 95% CI 0.06-0.28). Delay in chest tube drainage more than 2 days was not independently correlated with mortality. The initial biochemical diagnostics of non-purulent pleural effusions (63%) did not follow the current international guidelines. CONCLUSION: Factors correlating independently with survival included the possible interventional parameters of fibrinolytic therapy, insufficient initial antimicrobial therapy, and having thoracic surgery treatment.


Subject(s)
Empyema, Pleural/mortality , Empyema, Pleural/pathology , Aged , Denmark , Empyema, Pleural/diagnosis , Female , Humans , Male , Middle Aged , Prognosis , Retrospective Studies , Risk Factors , Treatment Outcome
20.
Scand J Infect Dis ; 43(3): 165-9, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21108539

ABSTRACT

BACKGROUND: Our aims were to describe the aetiologies of culture-positive pleural infections and to evaluate the choice of empiric antimicrobial treatment regimens according to antimicrobial sensitivity, and to evaluate the possible influence of this on outcome. METHODS: All cases over a 9-y period were identified from 3 hospitals using the laboratory databases of the clinical microbiology departments, and were verified by evaluating the medical records. RESULTS: We identified 291 isolates in pleural fluid cultures from 158 patients. These included viridans streptococci (25%), Staphylococcus aureus (18%), anaerobic bacteria (17%), Enterobacteriaceae (12%), Staphylococcus epidermidis (10%), and Streptococcus pneumoniae (7%), with differences between nosocomial and community-acquired infections. The mortality (overall 27%) was highest among the patients with Enterobacteriaceae (50%) and S. aureus (36%) infections, and in patients with mixed infections (34%). The actual empiric treatment or the recommended penicillin plus metronidazole had low antimicrobial coverage (49%) compared to the proposed cefuroxime plus metronidazole (78%). Thoracentesis was often delayed (median 2 days). The adequacy of empiric antimicrobial therapy was independently correlated with mortality (odds ratio 0.43, 95% confidence interval 0.30-0.62). CONCLUSIONS: The early diagnosis of pleural infection could be optimized. In this North-European patient population, we suggest that the recommended empiric antimicrobial treatment be changed to cefuroxime plus metronidazole for community-acquired and nosocomial infections.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Bacterial Infections/microbiology , Empyema, Pleural/drug therapy , Empyema, Pleural/microbiology , Aged , Bacterial Infections/mortality , Community-Acquired Infections/drug therapy , Community-Acquired Infections/microbiology , Community-Acquired Infections/mortality , Cross Infection/drug therapy , Cross Infection/microbiology , Cross Infection/mortality , Early Diagnosis , Empyema, Pleural/mortality , Europe , Female , Humans , Male , Middle Aged , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL